Recursion Pharmaceuticals, Inc. (RXRX)
3.63
+0.19
(+5.52%)
USD |
NASDAQ |
Sep 04, 16:00
3.645
+0.02
(+0.41%)
After-Hours: 20:00
Recursion Pharmaceuticals SG&A Expense (TTM) : 151.41M for June 30, 2026
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 151.41M |
| March 31, 2026 | 156.53M |
| December 31, 2025 | 176.59M |
| September 30, 2025 | 220.12M |
| June 30, 2025 | 216.25M |
| March 31, 2025 | 201.43M |
| December 31, 2024 | 178.18M |
| September 30, 2024 | 131.46M |
| June 30, 2024 | 122.90M |
| March 31, 2024 | 119.36M |
| December 31, 2023 | 110.82M |
| September 30, 2023 | 100.20M |
| June 30, 2023 | 90.49M |
| Date | Value |
|---|---|
| March 31, 2023 | 83.40M |
| December 31, 2022 | 81.60M |
| September 30, 2022 | 80.96M |
| June 30, 2022 | 77.16M |
| March 31, 2022 | 69.82M |
| December 31, 2021 | 57.68M |
| September 30, 2021 | 38.48M |
| June 30, 2021 | 29.76M |
| March 31, 2021 | 21.06M |
| December 31, 2020 | 17.68M |
| September 30, 2020 | 17.68M |
| June 30, 2020 | 10.72M |
| March 31, 2020 | 5.561M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Twist Bioscience Corp. | 290.29M |
| Absci Corp. | 35.28M |
| Novavax, Inc. | 121.22M |
| Editas Medicine, Inc. | 45.51M |
| Halozyme Therapeutics, Inc. | 238.00M |